Cite
Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial
MLA
Veerle Stouten, et al. “Five-Year Treat-to-Target Outcomes after Methotrexate Induction Therapy with or without Other CsDMARDs and Temporary Glucocorticoids for Rheumatoid Arthritis in the CareRA Trial.” Annals of the Rheumatic Diseases, vol. 80, Apr. 2021, pp. 965–73. EBSCOhost, https://doi.org/10.1136/annrheumdis-2020-219825.
APA
Veerle Stouten, Kristien Van der Elst, Rene Westhovens, Johan Joly, Diederik De Cock, D. Bertrand, S. Pazmino, & Patrick Verschueren. (2021). Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial. Annals of the Rheumatic Diseases, 80, 965–973. https://doi.org/10.1136/annrheumdis-2020-219825
Chicago
Veerle Stouten, Kristien Van der Elst, Rene Westhovens, Johan Joly, Diederik De Cock, D. Bertrand, S. Pazmino, and Patrick Verschueren. 2021. “Five-Year Treat-to-Target Outcomes after Methotrexate Induction Therapy with or without Other CsDMARDs and Temporary Glucocorticoids for Rheumatoid Arthritis in the CareRA Trial.” Annals of the Rheumatic Diseases 80 (April): 965–73. doi:10.1136/annrheumdis-2020-219825.